Prevalence and management of lower urinary tract symptoms in methamphetamine abusers: an under-recognized clinical identity.

[1]  R. Moratalla,et al.  The role of dopamine receptors in the neurotoxicity of methamphetamine , 2013, Journal of internal medicine.

[2]  M. Watabe,et al.  Involvement of the α1D-adrenergic Receptor in Methamphetamine-Induced Hyperthermia and Neurotoxicity in Rats , 2013, Neurotoxicity Research.

[3]  Seung-June Oh,et al.  Efficacy and Safety of Tamsulosin for Treating Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled, Open-Label Non-Inferiority Study , 2012, Korean journal of urology.

[4]  S. Kish,et al.  Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. , 2012, Drug and alcohol dependence.

[5]  Eduardo D. Martín,et al.  Nrf2 deficiency potentiates methamphetamine‐induced dopaminergic axonal damage and gliosis in the striatum , 2011, Glia.

[6]  R. Walker,et al.  Urinary dysfunction in Parkinson's disease: a review. , 2009, Parkinsonism & related disorders.

[7]  J. Cadet,et al.  Molecular bases of methamphetamine-induced neurodegeneration. , 2009, International review of neurobiology.

[8]  Stephen J. Kish,et al.  Pharmacologic mechanisms of crystal meth , 2008, Canadian Medical Association Journal.

[9]  A. Wein,et al.  Pharmacology of the Lower Urinary Tract: Basis for Current and Future Treatments of Urinary Incontinence , 2004, Pharmacological Reviews.

[10]  M. Caruso,et al.  Acute, transient urinary retention from combined ecstasy and methamphetamine use. , 2004, The Journal of emergency medicine.

[11]  Choal Hee Park,et al.  Efficacy of Low-Dose Tamsulosin on Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia , 2004, Clinical drug investigation.

[12]  R. Rothman,et al.  Monoamine transporters and psychostimulant drugs. , 2003, European journal of pharmacology.

[13]  L. Heimer.  A new anatomical framework for neuropsychiatric disorders and drug abuse. , 2003, The American journal of psychiatry.

[14]  G. C. Wagner,et al.  Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. , 2003, Journal of pharmacological sciences.

[15]  D. Greene,et al.  ‘The agony and the ecstasy’: acute urinary retention after MDMA abuse , 2003, BJU international.

[16]  Y. Na,et al.  Efficacy of Low-Dose Tamsulosin in Chinese Patients with Symptomatic Benign Prostatic Hyperplasia , 2003, Clinical drug investigation.

[17]  E. Lee.  Comparison of Tamsulosin and Finasteride for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia in Korean Patients , 2002, The Journal of international medical research.

[18]  J. Glowinski,et al.  d-Amphetamine Fails to Increase Extracellular Dopamine Levels in Mice Lacking α1b-Adrenergic Receptors: Relationship between Functional and Nonfunctional Dopamine Release , 2002, The Journal of Neuroscience.

[19]  H. Kalant,et al.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[20]  G. S. Marks,et al.  DISTRIBUTION OF α‐ AND β‐ADRENOCEPTORS IN HUMAN URINARY BLADDER , 1974 .